Ph.D. 1997 Molecular Toxicology/Oncology New York University
M.S. 1994 Molecular Toxicology New York University


July, 2013-present
Professor
Department of Pharmacology and Toxicology
College of Pharmacy
University of Arizona
Research Field: The Nrf2/Keap1 Signaling pathway

July, 2011-June, 2013
Associate Professor
Department of Pharmacology and Toxicology
College of Pharmacy
University of Arizona
Research Field: The Nrf2/Keap1 Signaling pathway

September, 2005-June, 2011
Assistant Professor
Department of Pharmacology and Toxicology
College of Pharmacy
University of Arizona
Research Field: The Nrf2/Keap1 Signaling pathway

September, 1999-August, 2005
Research Assistant Professor
Biochemistry Department, University of Missouri-Columbia
Research Field: The Nrf2/Keap1 Signaling pathway
The NFkB/IkB Signaling pathway

January, 1999-August, 1999
Lecturer
Department of Biological Sciences, University of Missouri-Rolla
Courses taught: General Biology (BioSc. 110) and Virology (BioSc 391)

May, 1997-December, 1998
Postdoctoral Fellow
DuPont-Haskell Laboratories, Inhalation Toxicology, Newark, DE
Research Field: Crystalline Silica Induced Apoptosis in the Lungs of Exposed Rats
Supervisor: Dr. David B. Warheit

September, 1994-May, 1997
Graduate Research Associate
Sackler Institute of Graduate Biomedical Sciences, Department of Environmental Health Sciences
Nelson Institute of Environmental Medicine, New York University Medical Center
Dissertation: Identification and Characterization of a Novel Gene Specifically Induced by Ni2+
Thesis Advisor: Dr. Max Costa

January, 1992 – September, 1994
Graduate Research Associate
Nelson Institute of Environmental Medicine, New York University Medical Center
Master’s Thesis: Atherogenicity of Environmental Tobacco Smoke:
Molecular Mechanism of Human Arteriosclerosis
Advisor: Dr. Arthur Penn


Society of Toxicology (SOT)
American Association for Cancer Research (AACR)


2012-2016      Member, NIH Review Committee: Chemo/Dietary Prevention Study Section
2011                President, Mountain West Regional Chapter, Society of Toxicology
2011                Symposium Chair, “New insights into the Nrf2-Keap1 pathway and its impact on human disease,” 50th Anniversary of Society of Toxicology annual meeting, Washington, D. C.
2010                Editor, “Nrf2-Keap1” forum, Antioxidants & Redox Signaling
2010                Reviewer, National Science Foundation Panel: Molecular and Cellular Biosciences Division
2010                Symposium Chair, “Cellular & Molecular Responses to BRIs,” Biological Reactive Intermediates VIII, Barcelona, Spain.
2009-              Editorial Board, Toxicology and Applied Pharmacology
2007-2011      Member, Career Resource and Development Committee, Society of Toxicology
1996-              Member, American Association for Cancer Research
1996-              Member, Society of Toxicology


2012: The Society of Toxicology Achievement Award
2006: NIH/NIEHS Outstanding New Environmental Health Scientist Award
1999: DuPont Young Investigator Award


1997 Homo Sapiens NIS (Cap 43) Gene, GenBank Accession # AF004162 (also called DRg1/Ndeg1/Rit42)


Pharmacology and Toxicology Seminar Coordinator
College of Pharmacy Computer and Information Services Committee

Training faculty for the Biological Chemistry Program (BCP)
Training faculty for the Cancer Biology Program
Training faculty for the training grant program in Toxicology and Toxicogenomics
Member of Cancer Prevention and Control at AZCC
Member of SWEHS


Cell communications and signal transduction* (PCOL630B)
*Course Coordinator
Case studies in Biochemical Pharmacology (PCOL820)
Pharmacy (PCOL871A)
Pharmacy (PCOL871b)
Advanced Toxicology (PCOL596C)


Ongoing Research Support:
08/15/2011-05/31/2016          
R01 CA154377, NIH/NCI, 3.00 calendar
“Investigation of an anti-cancer phytochemical targeting Nrf2”
PI: Donna D. Zhang    $1,250,000 direct
Objective: The goal of the proposed research is to characterize the anti-cancer properties of brusatol, an inhibitor of the Nrf2 pathway, using a preclinical lung cancer model and delineate the molecular targets and mechanistic actions of brusatol.

05/01/2012-01/31/2016          
2R01 ES015010, NIH/NIEHS, 3.00 calendar
“The protective role of Nrf2 in arsenic-induced toxicity and carcinogenicity”
PI: Donna D. Zhang    $800,000 direct
Objective: The major goals of this project are to define the protection of the transcription factor Nrf2 against arsenic-induced toxicity and carcinogenicity

01/01/2013-12/31/2014          
R21 CA166926,          NIH/NCI, 1.20 calendar                                 
“Targeting colorectal carcinogenesis using a cinnamon-derived food factor”
MPI: Donna D. Zhang / Georg T. Wondrak    $275,000 direct
Objective: This project is to test the overall hypothesis that the cinnamon-derived food factor cinnamaldehyde represents a potent chemopreventive dietary factor targeting colorectal carcinogenesis through modulation of Nrf2-orchestrated cytoprotective mechanisms.

Completed Research Support:
09/01/2006-04/30/2012          
R01 ES015010, NIH/NIEHS, 6.00 calendar
“The Protective Role of Nrf2 in Arsenic-Induced Toxicity and Carcinogenicity”
PI: Donna D. Zhang    $1,625,000 direct
Objective: The major goals of this project are to define the protection of the transcription factor Nrf2 against arsenic-induced toxicity and carcinogenicity

07/01/2007-06/30/2012          
RSG-07-154-01-CNE, American Cancer Society, 3.00 calendar
“Regulation of the Transcription Factor Nrf2 by Chemopreventive Compounds”
PI: Donna D. Zhang    $600,000 direct
Objective: The major goals of this project are to define the mechanism of Nrf2 regulation in response to the treatment of chemopreventive compounds.